Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 24Leukemia, Myeloid, Chronic-Phase 4Leukemia 3Bronchiolitis Obliterans Syndrome 3Philadelphia Chromosome 2Myeloproliferative Disorders 2Leukemia, Myeloid 2Recurrence 1Hematologic Diseases 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Imatinib Mesylate 9fludarabine 5Whole-Body Irradiation 5Tacrolimus 5Mycophenolic Acid 5Cyclophosphamide 5Busulfan 5ponatinib 4nilotinib 4fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Cytarabine 3Bone Marrow Transplantation 3venetoclax 2thymoglobulin 2asciminib 2Sirolimus 2Patient Reported Outcome Measures 2Methotrexate 2Mesna 2Melphalan 2Dasatinib 2Behavior Therapy 2Azacitidine 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2zileuton 1spartalizumab 1sabatolimab 1nicotinamide-beta-riboside 1methanesulfonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myeloid × asciminib × Myeloid × Clear all
NCT05143840 2026-06-02

ALERTCML

University of Alabama at Birmingham

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03578367 2026-04-21

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Novartis

Phase 2 Completed
104 enrolled 33 charts
MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡